South Korea’s two leading drugmakers, Celltrion Inc. and Samsung Bioepis Co., have achieved a significant milestone in the European biosimilar market, capturing over 50% market share in the six ...

Of the 50 different drugs approved by the U.S. Food and Drug Administration (FDA) in 2024, 18 of these agents were biosimilars, eight of which target reference products with no previous biosimilar ...